Evotec is a leading global drug discovery partnership organization with expertise in multiple therapeutics areas including infectious disease. Forge & Evotec formed a strategic relationship in 2016 to advance the LpxC program and expanded in 2017 to further develop the BLACKSMITH platform. In addition, Evotec is an investor in Forge’s Series A financing.
Forge partners with Syngene on select chemistry activities including analoging, building block synthesis, and scale-up. Syngene is India’s largest contract research organization.
CARB-X is the world’s largest public-private partnership dedicated to supporting the discovery of antibiotics targeting Gram-negative bacteria. CARB-X has over $450M in funding to support a portfolio of new innovative drug discovery programs. Forge was the largest recipient of the inagural CARB-X awards.
Forge is collaborating with Dr. Spellberg on the development of antibiotics to treat multi (MDR) and extensively drug resistant (XDR) bacteria infections.